专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080267936A1 Treatment of trauma-hemorrhage with short oligopeptides 审中-公开
标题翻译：用短寡肽治疗创伤性出血
公开(公告)号：US20080267936A1
公开(公告)日：2008-10-30
申请号：US12069741
申请日：2008-02-12
申请人： Nisar Ahmed Khan , Robert Benner
发明人： Nisar Ahmed Khan , Robert Benner
IPC分类号： A61K35/16 , A61K38/05 , A61K38/06 , A61K38/07 , G01N33/567 , A61K35/18 , A61K38/08 , A61K35/14
CPC分类号： A61K38/07 , A61K38/04 , A61K38/24 , C07K5/1008 , C07K5/101 , G01N33/6863 , G01N2333/525 , G01N2333/5412 , G01N2500/00
摘要： Described are methods and associated means for treating a subject, such as a mammal, experiencing or thought to be at risk for hemorrhagic shock. Such methods include administering to the subject in a medically acceptable manner, a short oligopeptide such as AQGV (SEQ ID NO:1) and/or LQGV (SEQ ID NO:2).
摘要翻译：描述了用于治疗体验或被认为具有出血性休克风险的受试者（例如哺乳动物）的方法和相关手段。这样的方法包括以医学上可接受的方式给予受试者短的寡肽如AQGV（SEQ ID NO：1）和/或LQGV（SEQ ID NO：2）。

2. 发明授权

US08288341B2 Control of radiation injury 有权
标题翻译：辐射伤害控制
公开(公告)号：US08288341B2
公开(公告)日：2012-10-16
申请号：US12460317
申请日：2009-07-15
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/06 , A61K38/07 , A61K38/08
CPC分类号： A61K9/0019 , A61K38/08
摘要： Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of an amino acid molecule selected from the group consisting of VVC, LAG, AQG, LQGV, QVVC, MTRV, LAGV, LQAV, PGCP, VGQL, RVLQ, EMFQ, AVAL, FVLS, NMWD, LCFL, FSYA, FWVD, AFTV, LGTL, QLLG, YAIT, APSL, ITTL, QALG, GVLC, NLIN, SPIE, LNTI, LHNL, CPVQ, EVVR, MTEV, EALE, EPPE, LGTL, VGGI, RLPG, LQGA, LCFL, TLAVE, VEGNL, LNEAL, CPRGVNP, MGGTWA, LTCDDP, VCNYRDV, QPLAPLVG, and DINGFLPAL. The invention provides for administration of the peptide prior to and following exposure of the subject to a source of radiation.
摘要翻译：治疗有需要的受试者的放射线损伤的方法包括向受试者施用由VVC，LAG，AQG，LQGV，QVVC，MTRV，LAGV，LQAV，PGCP，VGQL， RVLQ，EMFQ，AVAL，FVLS，NMWD，LCFL，FSYA，FWVD，AFTV，LGTL，QLLG，YAIT，APSL，ITTL，QALG，GVLC，NLIN，SPIE，LNTI，LHNL，CPVQ，EVVR，MTEV，EALE，EPPE， LGTL，VGGI，RLPG，LQGA，LCFL，TLAVE，VEGNL，LNEAL，CPRGVNP，MGGTWA，LTCDDP，VCNYRDV，QPLAPLVG和DINGFLPAL。本发明提供了在受试者暴露于辐射源之前和之后对肽的施用。

3. 发明申请

US20090227505A1 Methods and uses for protein breakdown products 审中-公开
标题翻译：蛋白质分解产物的方法和用途
公开(公告)号：US20090227505A1
公开(公告)日：2009-09-10
申请号：US12386061
申请日：2009-04-09
申请人： Nisar Ahmed Khan , Robbert Benner
发明人： Nisar Ahmed Khan , Robbert Benner
IPC分类号： C07K5/08 , C07K5/10 , C07K7/06 , C07K7/08 , C07K14/00 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/16 , A61P29/00 , A61P3/00
CPC分类号： A61K38/08 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1021 , C07K5/1024 , C07K7/06
摘要： Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory compounds. For instance, certain short breakdown products of hCG (i.e., short peptides which can easily be synthesized, if needed modified, and used as a pharmaceutical composition) exert a major regulatory activity on pro- or anti-inflammatory cytokine cascades that are governed by a family of crucial transcription factors, the NF-κB family, which generally regulate the expression of genes involved in the body's immune response.
摘要翻译：通常认为蛋白质的最小分解产物本身没有特定的生物学功能，现在可以发现身体可以利用正常的蛋白水解分解过程产生重要的化合物，如基因调控化合物。例如，hCG的某些短分解产物（即，可以容易地合成的短肽，如果需要修饰，并用作药物组合物）对由或由α受体拮抗剂组成的促炎细胞因子或抗炎细胞因子级联发挥主要的调节活性关键转录因子家族，NF-kappaB家族，其通常调节参与身体免疫应答的基因的表达。

4. 发明申请

US20090042807A1 Oligopeptide treatment of ischemia reperfusion injury 审中-公开
标题翻译：寡肽治疗缺血再灌注损伤
公开(公告)号：US20090042807A1
公开(公告)日：2009-02-12
申请号：US12074020
申请日：2008-02-29
申请人： Nisar Ahmed Khan , Robbert Benner , Bartholomeus Caspar Jacobs
发明人： Nisar Ahmed Khan , Robbert Benner , Bartholomeus Caspar Jacobs
IPC分类号： A61K38/08 , A61K38/07 , A61P9/10
CPC分类号： A61K38/24 , A61K38/1709
摘要： The invention relates to the modulation of gene expression in a cell, also called gene control, in particular, in relation to the treatment of ischemic-reperfusion injury. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof. The invention provides a method of treating ischemia-reperfusion injury in a subject by reducing NO production by the subject's macrophages, the method comprising: administering to the subject a composition comprising: means for reducing production of NO by a cell, together with a pharmaceutically acceptable excipient.
摘要翻译：本发明涉及细胞中基因表达的调节，也称为基因控制，特别是涉及缺血再灌注损伤的治疗。本发明提供了调节细胞中基因表达的方法，包括向细胞提供包含肽或其功能类似物的信号分子。本发明提供了一种通过减少受试者的巨噬细胞的NO产生来治疗受试者的缺血再灌注损伤的方法，所述方法包括：向受试者施用组合物，其包含：用于减少细胞产生NO的装置，以及药学上可接受的赋形剂。

5. 发明授权

US08680059B2 Oligopeptide acetate and formulations thereof 有权
标题翻译：醋酸寡肽及其制剂
公开(公告)号：US08680059B2
公开(公告)日：2014-03-25
申请号：US11600294
申请日：2006-11-15
申请人： Nisar Ahmed Khan , Robbert Benner
发明人： Nisar Ahmed Khan , Robbert Benner
IPC分类号： A61K38/06 , C09D101/14
CPC分类号： C07K5/1008 , A61K38/00 , C07K5/101
摘要： The invention relates to acetates of the tetrapeptides AQGV (SEQ ID NO:2) and LQGV (SEQ ID NO:3), pharmaceutical compositions comprising the acetates of the tetrapeptides, and methods of treating using the acetates of the tetrapeptides or pharmaceutical compositions to treat acute inflammatory conditions including sepsis.
摘要翻译：本发明涉及四肽AQGV（SEQ ID NO：2）和LQGV（SEQ ID NO：3）的乙酸盐，包含四肽的乙酸盐的药物组合物，以及使用四肽或药物组合物的乙酸盐处理的方法急性炎症状况包括败血症。

6. 发明授权

US07560433B2 Treatment of multiple sclerosis (MS) 有权
标题翻译：多发性硬化症（MS）治疗
公开(公告)号：US07560433B2
公开(公告)日：2009-07-14
申请号：US10409630
申请日：2003-04-08
申请人： Nisar Ahmed Khan , Robbert Benner
发明人： Nisar Ahmed Khan , Robbert Benner
IPC分类号： A61K38/00 , A61K38/02 , A61K38/07 , A61K38/24
CPC分类号： C07K14/59 , A61K38/00 , C07K5/06008 , C07K5/06026 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K7/06 , C07K7/08
摘要： The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing/remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing/remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing/remitting disease as seen with multiple sclerosis.
摘要翻译：本发明涉及治疗多发性硬化，特别是治疗在疾病进展阶段中看到的炎性损伤，例如经常被称为“复发”或“恶化”或“急性发作”的急性疾病的复发性高潮，复发/缓解“多发性硬化症中出现的疾病。本发明提供了一种调节患有其中的受试者的复发/缓解性疾病的方法，所述方法包括向受试者提供基因调节肽或其功能类似物。此外，本发明提供了NF-κB下调肽或其功能类似物在制备用于治疗多发性硬化症所见的复发/缓解性疾病的药物组合物中的用途。

7. 发明授权

US07358330B2 Immunoregulatory compositions 有权
标题翻译：免疫调节组合物
公开(公告)号：US07358330B2
公开(公告)日：2008-04-15
申请号：US10753510
申请日：2004-01-07
申请人： Nisar Ahmed Khan , Robbert Benner
发明人： Nisar Ahmed Khan , Robbert Benner
IPC分类号： C07K5/103 , A61K38/07
CPC分类号： A61K38/08 , C07K4/00 , C07K5/06008 , C07K5/06026 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1021 , C07K5/1024 , C07K7/06 , C07K7/08 , C07K14/59
摘要： The invention relates to compounds exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequence AAL AAQ AAG AAV wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu; wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala; wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein AAV is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Val and Ala. In one embodiment, the compound consists of a tripeptide selected from the group AQG, MTR, VVC, and mixtures thereof.
摘要翻译：本发明涉及通过测定化合物调节细胞产生NO的能力而确定的具有免疫调节活性的化合物。优选的化合物包括或由序列组成<？in-line-formula description =“In-line Formulas”end =“lead”？> AAL AAQ AAG AAV <？in-line-formula description =“In-line Formulas”end =“尾”→其中AAL是选自Ala和Leu的取代或未取代的非极性氨基酸; 其中AAQ是选自Gln，Pro和Ala的取代或未取代的氨基酸; 其中AAG是取代或未取代的氨基酸Gly，其中AAV是选自Val和Ala的取代或未取代的非极性氨基酸。在一个实施方案中，该化合物由选自AQG， MTR，VVC及其混合物。

8. 再颁专利

USRE43309E1 Immunoregulatory compositions 有权
标题翻译：免疫调节组合物
公开(公告)号：USRE43309E1
公开(公告)日：2012-04-10
申请号：US13065317
申请日：2011-03-17
申请人： Nisar Ahmed Khan , Robbert Benner
发明人： Nisar Ahmed Khan , Robbert Benner
IPC分类号： C07K5/103 , A61K38/07
CPC分类号： C07K5/06008 , A61K38/00 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/17 , C07K5/06026 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K7/06 , C07K7/08 , C07K14/59
摘要： The invention relates to compounds exhibiting immuno-regulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequence AAL AAQ AAG AAV wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu; wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala; wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein AAV is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Val and Ala. In one embodiment, the compound consists of a tripeptide selected from the group AQG, MTR, VVC, and mixtures thereof.
摘要翻译：本发明涉及通过测量化合物调节细胞产生NO的能力而确定的显示免疫调节活性的化合物。优选的化合物包括或由AAL AAQ AAG AAV序列组成，其中AAL是选自Ala和Leu的取代或未取代的非极性氨基酸; 其中AAQ是选自Gln，Pro和Ala的取代或未取代的氨基酸; 其中AAG是取代或未取代的氨基酸Gly，其中AAV是选自Val和Ala的取代或未取代的非极性氨基酸。在一个实施方案中，该化合物由选自AQG， MTR，VVC及其混合物。

9. 发明授权

US07795226B2 Control of radiation injury 有权
标题翻译：辐射伤害控制
公开(公告)号：US07795226B2
公开(公告)日：2010-09-14
申请号：US11715314
申请日：2007-03-07
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/07 , A61K38/04
CPC分类号： A61K9/0019 , A61K38/08
摘要： Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of the amino acid sequence AQGV. The invention provides for administration of the amino acid composition prior to and following exposure of the subject to a source of radiation.
摘要翻译：治疗有需要的受试者的放射线损伤的方法包括向受试者施用由氨基酸序列AQGV组成的肽。本发明提供了在受试者暴露于辐射源之前和之后给予氨基酸组合物。

10. 发明申请

US20090281033A1 Control of radiation injury 审中-公开
公开(公告)号：US20090281033A1
公开(公告)日：2009-11-12
申请号：US12288935
申请日：2008-10-24
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/16 , A61K38/10 , A61K38/08 , A61K38/07 , A61K38/06 , A61K38/05 , A61P43/00
CPC分类号： A61K9/0019 , A61K38/08
摘要： The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式